Recent Advances in the Management of Typical and Atypical Lung Carcinoids

被引：21

作者：

Prinzi, Natalie ^{[1
]}

Rossi, Roberta Elisa ^{[2
,5
]}

Proto, Claudia ^{[1
]}

Leuzzi, Giovanni ^{[3
]}

Raimondi, Alessandra ^{[1
]}

Torchio, Martina ^{[1
]}

Milione, Massimo ^{[4
]}

Corti, Francesca ^{[1
]}

Colombo, Elena ^{[1
]}

Prisciandaro, Michele ^{[1
]}

Cascella, Tommaso ^{[6
]}

Spreafico, Carlo ^{[6
]}

Beninato, Teresa ^{[1
]}

Coppa, Jorgelina ^{[2
]}

Lo Russo, Giuseppe ^{[1
]}

Di Bartolomeo, Maria ^{[1
]}

de Braud, Filippo ^{[1
,7
]}

Pusceddu, Sara ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Gastrointestinal Surg & Liver Transplantat Unit, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Div Thorac Surg, Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Diagnost Pathol & Lab Med Dept, Milan, Italy

[5] Univ Milan, Dept Pathophysiol & Organ Transplant, Milan, Italy

[6] Fdn IRCCS Ist Nazl Tumori, Radiol Dept, Milan, Italy

[7] Univ Milan, Oncol & Hematooncol Dept, Milan, Italy

来源：

CLINICAL LUNG CANCER | 2021年 / 22卷 / 03期

关键词：

Bronchial neuroendocrine tumors; Diagnosis; Epidemiology; Therapy; Typical carcinoid; PULMONARY NEUROENDOCRINE TUMORS; RECEPTOR RADIONUCLIDE THERAPY; LONG-TERM SURVIVAL; TEMOZOLOMIDE-BASED THERAPY; SOMATOSTATIN ANALOGS; BRONCHIAL CARCINOIDS; SURGICAL-MANAGEMENT; SUBLOBAR RESECTION; PROGNOSTIC-FACTORS; PHASE-II;

D O I：

10.1016/j.cllc.2020.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neuroendocrine neoplasms of the lung represent about 20% to 30% of all neuroendocrine tumors. On the basis of clinical and pathologic characteristics, 2 different categories of tumors may be defined: poorly differentiated neuroendocrine neoplasms, characterized by a high rate of recurrences and poor prognosis, and well-differentiated neuroendocrine neoplasms (typical carcinoids and atypical carcinoids), which generally display an indolent course. Lung carcinoids represent only 1% to 5% of all lung malignancies, but their incidence has significantly increased over the past 30 years. Surgery is the reference standard of treatment for lung carcinoids with locoregional disease. For advanced or unresectable lung carcinoids, several therapeutic options are available, but the choice should be shared within a multidisciplinary team to ensure optimal therapeutic outcomes. We describe the current management of these rare neoplasms. (C) 2020 Published by Elsevier Inc.

引用

页码：161 / 169

页数：9

共 119 条

[1] Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging [J].

Abgral, Ronan ;

Leboulleux, Sophie ;

Deandreis, Desiree ;

Auperin, Anne ;

Lumbroso, Jean ;

Dromain, Clarisse ;

Duvillard, Pierre ;

Elias, Dominique ;

de Baere, Thierry ;

Guigay, Joel ;

Ducreux, Michel ;

Schlumberger, Martin ;

Baudin, Eric .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) :665-671

[2] Is sublobar resection equivalent to lobectomy for surgical management of peripheral carcinoid? [J].

Afoke, Jonathan ;

Tan, Carol ;

Hunt, Ian ;

Zakkar, Mustafa .

INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2013, 16 (06) :858-863

[3] The ectopic ACTH syndrome [J].

Alexandraki, Krystallenia I. ;

Grossman, Ashley B. .

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2010, 11 (02) :117-126

[4] Bronchoplastic Procedures for Carcinoid Tumors [J].

Anile, Marco ;

Diso, Daniele ;

Rendina, Erino A. ;

Venuta, Federico .

THORACIC SURGERY CLINICS, 2014, 24 (03) :299-+

[5] Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? [J].

Antunes, P. ;

Ginj, M. ;

Zhang, H. ;

Waser, B. ;

Baum, R. P. ;

Reubi, J. C. ;

Maecke, H. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (07) :982-993

[6] Long-term outcomes and prognostic factors of patients with surgically treated pulmonary carcinoid: our institutional experience with 104 patients [J].

Aydin, Ertan ;

Yazici, Ulku ;

Gulgosteren, Mahmut ;

Agackiran, Yetkin ;

Kaya, Sadi ;

Gulhan, Erkmen ;

Tastepe, Irfan ;

Karaoglanoglu, Nurettin .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2011, 39 (04) :549-554

[7] Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? [J].

Bajetta, Emilio ;

Catena, Laura ;

Procopio, Giuseppe ;

De Dosso, Sara ;

Bichisao, Ettore ;

Ferrari, Leonardo ;

Martinetti, Antonia ;

Platania, Marco ;

Verzoni, Elena ;

Formisano, Barbara ;

Bajetta, Roberto .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) :637-642

[8] Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours [J].

Bodei, L ;

Cremonesi, M ;

Grana, C ;

Rocca, P ;

Bartolomei, M ;

Chinol, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (07) :1038-1046

[9] Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors [J].

Bodei, Lisa ;

Cremonesi, Marta ;

Kidd, Mark ;

Grana, Chiara M. ;

Severi, Stefano ;

Modlin, Irvin M. ;

Paganelli, Giovanni .

THORACIC SURGERY CLINICS, 2014, 24 (03) :333-+

[10] Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT [J].

Bongiovanni, Alberto ;

Recine, Federica ;

Riva, Nada ;

Foca, Flavia ;

Liverani, Chiara ;

Mercatali, Laura ;

Nicolini, Silvia ;

Pieri, Federica ;

Amadori, Dino ;

Ibrahim, Toni .

CLINICAL LUNG CANCER, 2017, 18 (04) :415-420

← 1 2 3 4 5 6 7 8 9 10 →